X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs DR. REDDYS LAB - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA DR. REDDYS LAB FULFORD INDIA/
DR. REDDYS LAB
 
P/E (TTM) x 398.8 29.1 1,372.4% View Chart
P/BV x 6.2 3.1 199.5% View Chart
Dividend Yield % 0.1 0.8 10.0%  

Financials

 FULFORD INDIA   DR. REDDYS LAB
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
DR. REDDYS LAB
Mar-18
FULFORD INDIA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs9422,788 33.8%   
Low Rs4501,902 23.7%   
Sales per share (Unadj.) Rs691.4860.8 80.3%  
Earnings per share (Unadj.) Rs11.557.1 20.1%  
Cash flow per share (Unadj.) Rs15.4122.0 12.6%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.30.9 33.7%  
Book value per share (Unadj.) Rs380.0757.7 50.1%  
Shares outstanding (eoy) m3.90165.91 2.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.02.7 37.0%   
Avg P/E ratio x60.741.1 147.8%  
P/CF ratio (eoy) x45.319.2 235.8%  
Price / Book Value ratio x1.83.1 59.2%  
Dividend payout %17.435.0 49.8%   
Avg Mkt Cap Rs m2,714389,034 0.7%   
No. of employees `0000.423.5 1.9%   
Total wages/salary Rs m50532,149 1.6%   
Avg. sales/employee Rs Th6,073.06,070.8 100.0%   
Avg. wages/employee Rs Th1,137.41,366.6 83.2%   
Avg. net profit/employee Rs Th100.7402.5 25.0%   
INCOME DATA
Net Sales Rs m2,696142,810 1.9%  
Other income Rs m1251,552 8.1%   
Total revenues Rs m2,822144,362 2.0%   
Gross profit Rs m-4623,512 -0.2%  
Depreciation Rs m1510,772 0.1%   
Interest Rs m10788 1.2%   
Profit before tax Rs m5413,504 0.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m104,380 0.2%   
Profit after tax Rs m459,468 0.5%  
Gross profit margin %-1.716.5 -10.5%  
Effective tax rate %17.732.4 54.5%   
Net profit margin %1.76.6 25.0%  
BALANCE SHEET DATA
Current assets Rs m1,738104,984 1.7%   
Current liabilities Rs m54568,938 0.8%   
Net working cap to sales %44.325.2 175.4%  
Current ratio x3.21.5 209.6%  
Inventory Days Days4874 65.2%  
Debtors Days Days4104 4.2%  
Net fixed assets Rs m12104,385 0.0%   
Share capital Rs m39830 4.7%   
"Free" reserves Rs m1,443124,886 1.2%   
Net worth Rs m1,482125,716 1.2%   
Long term debt Rs m025,089 0.0%   
Total assets Rs m2,077225,443 0.9%  
Interest coverage x6.718.1 37.0%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x1.30.6 205.0%   
Return on assets %2.64.5 57.4%  
Return on equity %3.07.5 40.0%  
Return on capital %4.39.7 44.4%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1772,623 0.0%   
Fx outflow Rs m67318,916 3.6%   
Net fx Rs m-65653,707 -1.2%   
CASH FLOW
From Operations Rs m9018,030 0.5%  
From Investments Rs m105-14,883 -0.7%  
From Financial Activity Rs m-14-4,440 0.3%  
Net Cashflow Rs m181-1,236 -14.6%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 5.4 70.4%  
FIIs % 0.1 35.3 0.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 21.2 15.3 138.6%  
Shareholders   4,783 75,885 6.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare FULFORD INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 8-QTR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS